Marvel Biosciences Invited to Test MB-204 on Autism by French University

Calgary, Alberta (November 16, 2023)– Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce a collaboration with Dr. Julie Le Merrer and Dr. Jerome Becker at iBrain Institute, Tours, France to study the effects of MB-204 in mouse models of autism. “We are very pleased to have...

Marvel Announces Successful Completion of Toxicology Study in Preparation for Phase 1 Human Trials

Calgary, Alberta (August 22, 2023)– Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has successfully completed its 4-week good laboratory practice (GLP), FDA investigational new drug (IND), dose-ranging dog and rat studies for its lead drug candidate MB-204 paving...

Marvel Highlights Key Asset at the 2023 Alzheimer’s Association International

Calgary, Alberta – (July 10,  2023) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has been selected to present the Company’s scientific advancement of its key asset MB-204 titled MB-204: A Novel Adenosine A2a Antagonist for AD, ADHD and Depression at the Alzheimer's...

Marvel Successfully Completes the Dog and Rat GLP Toxicology Studies Required to Enter Human Trials

Calgary, Alberta – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has completed the dosing portion of the 4-week good laboratory practice (GLP) FDA investigational new drug (IND) enabling dose-ranging dog and rat studies for its lead drug candidate MB-204.  “We are pleased...

Marvel Commence Final Study Required Prior to Initiating Human Trials

Calgary, Alberta – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has initiated the 4-week good laboratory practice (GLP) FDA investigational new drug (IND) enabling dose-ranging dog studies for its lead drug candidate MB-204.   “This dog study is the last of the two...

Marvel Biosciences Initiates Four Week Rat GLP Toxicology Study

Calgary, Alberta – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has initiated the 4-week good laboratory practice (GLP) FDA investigational new drug (IND) enabling dose-ranging rat studies for its lead drug candidate MB-204. “This rat study, along with the GLP study on...

Marvel Biosciences Announces Closing of First Tranche of Debenture Offering

Calgary, Alberta – Marvel Biosciences Corp. ("Marvel" or the "Corporation") announced today that it has completed the closing of the first tranche of the previously announced non-brokered private placement of debentures (“Debentures”) for gross proceeds of $1,000,000 (the “Private Placement”), subject to final approval of the TSX Venture Exchange.   The Debentures bear interest at the rate of...

Marvel Biosciences Announces Proposed Debenture Offering

Calgary, Alberta – Marvel Biosciences Corp. ("Marvel" or the "Company") announced today its intention to complete a non-brokered private placement offering of unsecured convertible debentures (“Debentures”) in the principal amount of up to $1,500,000 (the “Private Placement”). The Debentures will bear interest at the rate of eight percent (8%) per annum, payable annually and will mature on the...

Marvel Biosciences Completes a Critical Manufacturing Milestone Required to Enter Phase 1 Human Trials Targeting Alzheimer’s Disease and Depression

Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has successfully completed a multi-kilogram scale run under current good manufacturing practices (“cGMP”) of the active pharmaceutical ingredient (API) of the Company’s lead asset MB-204 in partnership with Zhejiang Ausun...

Marvel Biosciences Successfully Completes its Short Term Dose Ranging Study in Rats and Dogs for MB-204

Marvel Biosciences Corp. (TSV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has successfully completed its dose-ranging toxicology studies in rats and dogs, for its lead drug candidate  MB-204. These studies will assist in determining the doses for the IND-enabling 4-week GLP toxicology studies.  ...